Background: Diabetes is related with increased cancer mortality across multiple cancer types. Its role in lung cancer\nmortality is still unclear. We aim to determine the prognostic value of fasting plasma glucose (FPG) and diabetes mellitus\nin patients with locally advanced non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy.\nMethods: One-hundred seventy patients with stage III NSCLC received definitive concurrent chemoradiotherapy from\n2010 to 2014. Clinico-pathological data and clinical outcome was retrospectively registered. Fifty-six patients (33%), met\ncriteria for type 2 diabetes mellitus (T2DM) at baseline. The prognostic value of FPG and other clinical variables was\nassessed. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplanâ??Meier method and\nCox proportional models and log-rank test were used.\nResults: With a median follow-up of 36 months, median PFS was 8.0 months and median OS was 15.0 months in\npatients with........................
Loading....